Merck Raises Long-Term Revenue Outlook to $70 Billion by Mid-2030s
Merck; revenue target; $70 billion; mid-2030s; Keytruda; new growth drivers
Lightning Step and Sunwave Achieve SOC 2 Type II Attestation, Strengthening Security and Trust Across Healthcare Technology
Lightning Step; Sunwave; SOC 2 Type II; Healthcare Technology; Security; Compliance
Sentynl Therapeutics Receives FDA Approval for ZYCUBO, First US Treatment for Rare Menkes Disease
Sentynl Therapeutics; ZYCUBO; FDA approval; Menkes disease; copper histidinate; Zydus Lifesciences
Novartis Licenses Undisclosed Radioligand Therapy Asset from China’s Zonsen PepLib Biotech
Novartis; Zonsen PepLib; radiopharma; radioligand therapy; licensing deal; China biotech
FDA Requests Flu Vaccine Label Updates for Febrile Seizure Risk in Young Children
FDA; flu vaccine; febrile seizures; label update; children; influenza vaccine
JPM26 Live Blog Day 2: GSK Stays the Course Amid Key Biopharma Updates
JPM26; GSK; J.P. Morgan Healthcare Conference; Day 2; AstraZeneca; Novo Nordisk; biotech
JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus
BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
Pfizer; Obesity Drugs; Metsera; Phase III Trials; Albert Bourla; JPM26; Patent Cliff
Eisai Licenses Nuvation Bio’s Taletrectinib for ROS1+ Lung Cancer in Europe and Asia
Eisai; Nuvation Bio; taletrectinib; ROS1+ NSCLC; licensing agreement; lung cancer
Eli Lilly and Nvidia Announce $1 Billion, Five-Year AI Co-Innovation Lab Partnership in Bay Area
Eli Lilly; Nvidia; AI lab; drug discovery; $1 billion; Bay Area; JPM 2026